This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
This guideline covers care for adults and young people (aged 10 years and older) with physical health problems that are completely or partly caused by an alcohol-use disorder. It aims to improve the health of people with alcohol-use disorders by providing recommendations on managing acute alcohol withdrawal and treating alcohol-related conditions.
This guideline covers home safety assessments, supplying and installing safety equipment and providing education and advice. It aims to prevent unintentional injuries among all children and young people aged under 15 but, in particular, those living in disadvantaged circumstances.
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
This guideline covers the care that should be offered to women with a twin or triplet pregnancy in addition to the routine care that is offered to all women during pregnancy. It aims to reduce the risk of complications and improve outcomes for women and their babies.
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with a confirmed diagnosis of community-acquired pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.
This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.
This guideline covers strategies, regulation, enforcement, surveillance and workforce development in relation to preventing unintentional injuries in the home, on the road and during outdoor play and leisure.
This guideline covers road speed limits, 20mph zones and engineering measures to reduce speed or make routes safer.
This guideline covers the nutrition of pregnant women, including women who are planning to become pregnant, mothers and other carers of children aged under 5 and their children. In particular, it aims to address disparities in the nutrition of low-income and other disadvantaged groups compared with the general population.
This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with a confirmed diagnosis of hospital-acquired pneumonia. It does not cover ventilator-associated pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline covers the rapid identification and early management of major trauma in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by improving the quality of their immediate care. It does not cover care for people with burns.
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
NICE is unable to make a recommendation about the use in the NHS of afatinib for advanced squamous non-small-cell lung cancer after platinum-based chemotherapy
Evidence-based recommendations on HealOzone (ozone-releasing device) for treating tooth decay (occlusal pit/fissure caries/root caries)
Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block
Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Evidence-based recommendations on ipilimumab (YERVOY) for treating previously untreated advanced (unresectable or metastatic) melanoma (skin cancer)
Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)
Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic breast cancer
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes
Evidence-based recommendations on rituximab (MabThera) for first-line maintenance treatment of follicular non-Hodgkin's lymphoma
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism (VTE) after total hip or knee replacement in adults
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer..
Evidence-based recommendations on the use of Riluzole (Rilutek) for treating motor neurone disease (MND)
Evidence-based recommendations on imatinib (Glivec) for treating unresectable (inoperable) and/or metastatic gastrointestinal stromal tumours (GISTs)
Evidence-based recommendations on bevacizumab (Avastin) with oxaliplatin and fluorouracil plus folinic acid or capecitabine for metastatic colorectal cancer
NICE is unable to make a recommendation about the use in the NHS of temsirolimus for treating relapsed or refractory mantle cell lymphoma because no evidence
Evidence-based recommendations on trastuzumab (Herceptin) for treating adenocarcinoma (HER2-positive metastatic gastric cancer/stomach cancer)
Evidence-based recommendations on botulinum toxin type A (Botox) for the prevention of headaches in adults with chronic migraine
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults previously treated with docetaxel
Evidence-based recommendations on lapatinib (Tyverb) or trastuzumab (Herceptin) combined with an aromatase inhibitor for the first-line treatment of..
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women
Evidence-based recommendations on peginterferon alfa (2a [Pegasys] or 2b [ViraferonPeg]) and ribavirin (Copegus or Rebetol) for treating chronic hepatitis C
Evidence-based recommendations on etanercept (Enbrel) infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis
Evidence-based recommendations on Pharmalgen (ALK-Abelló) for treating bee and wasp venom allergy
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)
Evidence-based recommendations on fingolimod (Gilenya) for treating highly active relapsing–remitting multiple sclerosis (MS)
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)
Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis
Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.